A randomized, controlled, feasibility study of RD-X19 in subjects with mild-to-moderate COVID-19 in the outpatient setting.

Whereas the TWAC in the saliva viral load primary end point did not reach statistical significance given the sample size of this study, the −0.47 log 10 copies/ml least squares mean difference in SARS‐CoV‐2 saliva viral load is comparable to the −0.41 log 10 copies/ml mean difference reported for the TWAC through day 7 for the pooled doses of casirivimab/imdevimab antibody cocktail via nasophary

also in 111,027 other papers